Non-Small Cell Lung Cancer Clinical Trial
— LIBRETTO-001Official title:
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.
Status | Recruiting |
Enrollment | 875 |
Est. completion date | February 28, 2026 |
Est. primary completion date | February 28, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years and older |
Eligibility | Key Inclusion Criteria: For Phase 1: - Participants with a locally advanced or metastatic solid tumor that: - Has progressed on or is intolerant to standard therapy, or - For which no standard therapy exists, or in the opinion of the Investigator, are not candidates for or would be unlikely to tolerate or derive significant clinical benefit from standard therapy, or - Decline standard therapy - Prior multikinase inhibitors (MKIs) with anti-RET activity are allowed - A RET gene alteration is not required initially. Once adequate PK exposure is achieved, evidence of RET gene alteration in tumor and/or blood is required as identified through molecular assays, as performed for clinical evaluation - Measurable or non-measurable disease as determined by RECIST 1.1 or RANO as appropriate to tumor type - Eastern Cooperative Oncology Group (ECOG) score of 0, 1, or 2 or Lansky Performance Score (LPS) greater than or equal to (=) 40 percent (%) (age less than [<] 16 years) with no sudden deterioration 2 weeks prior to the first dose of study treatment - Adequate hematologic, hepatic and renal function - Life expectancy of at least 3 months For Phase 2: As for phase 1 with the following modifications: - For Cohort 1: Participants must have received prior standard therapy appropriate for their tumor type and stage of disease, or in the opinion of the Investigator, would be unlikely to tolerate or derive clinical benefit from appropriate standard of care therapy - Cohorts 1 and 2: - Enrollment will be restricted to participants with evidence of a RET gene alteration in tumor - At least one measurable lesion as defined by RECIST 1.1 or RANO, as appropriate to tumor type and not previously irradiated - Cohorts 3 and 4: Enrollment closed - Cohort 5: - Cohorts 1-4 without measurable disease - MCT not meeting the requirements for Cohorts 3 or 4 - MTC syndrome spectrum cancers (e.g., MTC, pheochromocytoma), cancers with neuroendocrine features/differentiation, or poorly differentiated thyroid cancers with other RET alteration/activation may be allowed with prior Sponsor approval - cfDNA positive for a RET gene alteration not known to be present in a tumor sample - Cohort 6: Participants who otherwise are eligible for Cohorts 1, 2 or 5 who discontinued another RET inhibitor may be eligible with prior Sponsor approval - Cohort 7: Participants with a histologically confirmed stage IB-IIIA NSCLC and a RET fusion; determined to be medically operable and tumor deemed resectable by a thoracic surgical oncologist, without prior systemic treatment for NSCLC Key Exclusion Criteria (Phase 1 and Phase 2): - Phase 2 Cohorts 1 and 2: an additional known oncogenic driver - Cohorts 3 and 4: Enrollment closed - Cohorts 1, 2 and 5: prior treatment with a selective RET inhibitor Notes: Participants otherwise eligible for Cohorts 1, 2, and 5 who discontinued another selective RET inhibitor may be eligible for Phase 2 Cohort 6 with prior Sponsor approval - Investigational agent or anticancer therapy (including chemotherapy, biologic therapy, immunotherapy, anticancer Chinese medicine or other anticancer herbal remedy) within 5 half-lives or 2 weeks (whichever is shorter) prior to planned start of LOXO-292 (selpercatinib). In addition, no concurrent investigational anti-cancer therapy is permitted Note: Potential exception for this exclusion criterion will require a valid scientific justification and approval from the Sponsor - Major surgery (excluding placement of vascular access) within 2 weeks prior to planned start of LOXO-292 (selpercatinib) - Radiotherapy with a limited field of radiation for palliation within 1 week of planned start of LOXO-292 (selpercatinib), with the exception of participants receiving radiation to more than 30% of the bone marrow or with a wide field of radiation, which must be completed at least 4 weeks prior to the first dose of study treatment - Any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2, prior platinum-therapy related neuropathy - Symptomatic primary CNS tumor, metastases, leptomeningeal carcinomatosis, or untreated spinal cord compression. Participants are eligible if neurological symptoms and CNS imaging are stable and steroid dose is stable for 14 days prior to the first dose of LOXO-292 (selpercatinib) and no CNS surgery or radiation has been performed for 28 days, 14 days if stereotactic radiosurgery (SRS) - Clinically significant active cardiovascular disease or history of myocardial infarction within 6 months prior to planned start of LOXO-292 (selpercatinib) or prolongation of the QT interval corrected (QTcF) greater than (>) 470 milliseconds (msec) - Participants with implanted pacemakers may enter the study without meeting QTc criteria due to nonevaluable measurement if it is possible to monitor for QT changes. - Participants with bundle branch block may be considered for study entry if QTc is appropriate by a formula other than Fridericia's and if it is possible to monitor for QT changes. - Required treatment with certain strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers and certain prohibited concomitant medications - Phase 2 Cohort 7 (neoadjuvant treatment): Participant must not have received prior systemic therapy for NSCLC. |
Country | Name | City | State |
---|---|---|---|
Australia | Peter MacCallum Cancer Centre | Melbourne | Victoria |
Australia | Royal North Shore Hospital | St. Leonards | New South Wales |
Canada | BC Cancer Vancouver | Vancouver | British Columbia |
Denmark | Rigshospitalet | Copenhagen | København Ø |
France | Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest | Bordeaux | |
France | Centre Leon Berard | Lyon Cedex 08 | |
France | APHM Hôpital de la Timone | Marseille | |
France | Institut du Cancer de Montpellier - Val d'aurelle | Montpellier Cedex 5 | |
France | Hôpital Européen Georges Pompidou | Paris | Cedex 15 |
France | Gustave Roussy | Villejuif Cedex | |
Germany | Universitätsklinikum Köln | Köln | Nordrhein-Westfalen |
Germany | Universitätsklinikum Würzburg A. ö. R. | Würzburg | Bayern |
Hong Kong | Prince of Wales Hospital | Hong Kong | Shatin, New Territories |
Israel | Soroka Medical Center - Pediatric Outpatient Clinic | Beer-Sheva | |
Israel | Hadassah Medical Center | Jerusalem | |
Israel | Shaare Zedek Medical Center | Jerusalem | Yerushalayim |
Israel | Sheba Medical Center | Tel Hashomer | Ramat Gan |
Italy | Istituto Nazionale dei Tumori | Milano | Lombardie |
Japan | Hyogo Cancer Center | Akashi | Hyogo |
Japan | National Cancer Center Hospital | Chuo-ku | Tokyo |
Japan | National Hospital Organization Kyushu Cancer Center | Fukuoka | |
Japan | Kanazawa University Hospital | Kanazawa | Ishikawa |
Japan | National Cancer Center Hospital East | Kashiwa | Chiba |
Japan | Japanese Foundation for Cancer Research | Koto | Tokyo |
Japan | Tominaga Hospital | Nagaizumi-cho,Sunto-gun | Shizuoka |
Japan | Nagoya University Hospital | Nagoya | Aichi |
Japan | Okayama University Hospital | Okayama | |
Japan | Osaka City General Hospital | Osaka | |
Japan | Kindai University Hospital | Osaka Sayama-shi | Osaka |
Japan | Hokkaido University Hospital | Sapporo | Hokkaido |
Japan | Tottori University Hospital | Yonago | Tottori |
Korea, Republic of | National Cancer Center | Goyang-si | Gyeonggi-do |
Korea, Republic of | Seoul National University Bundang Hospital | Seongnam | Kyonggi-do |
Korea, Republic of | Asan Medical Center | Seoul | Seoul-teukbyeolsi [Seoul] |
Korea, Republic of | Samsung Medical Center | Seoul | Seoul-teukbyeolsi [Seoul] |
Korea, Republic of | Severance Hospital, Yonsei University Health System | Seoul | |
Singapore | National Cancer Centre Singapore | Singapore | |
Spain | Hospital Universitari Vall d'Hebron | Barcelona | Barcelona [Barcelona] |
Spain | Hospital Madrid Norte Sanchinarro | Madrid | |
Spain | Hospital Universitario Fundación Jiménez Díaz | Madrid | |
Switzerland | Kantonsspital Luzern | Luzern 16 | Luzern |
Taiwan | Taichung Veterans General Hospital | Taichung | |
Taiwan | National Taiwan University Hospital | Taipei | |
United Kingdom | Royal Marsden Hospital | Sutton | Surrey |
United States | University of Michigan | Ann Arbor | Michigan |
United States | Emory University | Atlanta | Georgia |
United States | University of Maryland Medical Center | Baltimore | Maryland |
United States | Dana-Farber Cancer Institute | Boston | Massachusetts |
United States | Massachusetts General Hospital | Boston | Massachusetts |
United States | Roswell Park Cancer Institute | Buffalo | New York |
United States | University of North Carolina | Chapel Hill | North Carolina |
United States | University of Chicago Medicine-Comprehensive Cancer Center | Chicago | Illinois |
United States | Cleveland Clinic Foundation | Cleveland | Ohio |
United States | Ohio State University Hospital | Columbus | Ohio |
United States | University of Texas Southwestern Medical Center at Dallas | Dallas | Texas |
United States | Sarah Cannon Research Institute at HealthOne | Denver | Colorado |
United States | City of Hope National Medical Center | Duarte | California |
United States | USO-Virginia Cancer Specialists, PC | Fairfax | Virginia |
United States | START Midwest | Grand Rapids | Michigan |
United States | University of Texas MD Anderson Cancer Center | Houston | Texas |
United States | Mayo Clinic in Florida | Jacksonville | Florida |
United States | University of California - San Diego | La Jolla | California |
United States | Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada |
United States | UCLA Medical Center | Los Angeles | California |
United States | University of Wisconsin-Madison Hospital and Health Clinic | Madison | Wisconsin |
United States | Vanderbilt University Medical Center | Nashville | Tennessee |
United States | Yale Cancer Center | New Haven | Connecticut |
United States | Ochsner Clinic Foundation | New Orleans | Louisiana |
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
United States | NYU Langone | New York | New York |
United States | Hoag Memorial Hospital Presbyterian | Newport Beach | California |
United States | Irvine Medical Center | Orange | California |
United States | Memorial Hospital Pembroke | Pembroke | Florida |
United States | Thomas Jefferson University | Philadelphia | Pennsylvania |
United States | University of Pennsylvania Hospital | Philadelphia | Pennsylvania |
United States | Oregon Health and Science University | Portland | Oregon |
United States | Mayo Clinic | Rochester | Minnesota |
United States | Washington University Medical School | Saint Louis | Missouri |
United States | Huntsman Cancer Institute | Salt Lake City | Utah |
United States | UCSF Medical Center at Mission Bay | San Francisco | California |
United States | Kaiser Permanente | Santa Clara | California |
United States | Mayo Clinic of Scottsdale | Scottsdale | Arizona |
United States | Kaiser Permanente Medical Center | Vallejo | California |
United States | Johns Hopkins University | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Loxo Oncology, Inc. | Eli Lilly and Company |
United States, Australia, Canada, Denmark, France, Germany, Hong Kong, Israel, Italy, Japan, Korea, Republic of, Singapore, Spain, Switzerland, Taiwan, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Phase 1: MTD | Incidence rate and category of dose limiting toxicities (DLTs) during the first 28-day cycle of LOXO-292 (selpercatinib) treatment | The first 28 days of treatment (Cycle 1) | |
Primary | Phase 1: RP2D | Phase 1: RP2D | The first 28 days of treatment (Cycle 1) and every cycle (28 days) for approximately 12 months (or earlier if the participant discontinues from the study) | |
Primary | Phase 2: Objective Response Rate | As assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or Response Assessment in Neuro-Oncology (RANO), as appropriate to tumor type, as assessed by independent review committee (IRC) | Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in participants who have not progressed. | |
Secondary | Phase 1: Number of Participants with a Treatment-Related Adverse Event(s) (TRAE[s]) | Phase 1: Number of Participants with a TRAE(s) | From the time of informed consent, for approximately 24 months (or earlier if the participant discontinues from the study), and through Safety Follow-up (28 days after the last dose) | |
Secondary | Phase 1: Number of Participants with an Abnormal Laboratory or Physical Exam Result(s) | Phase 1: Number of Participants with an Abnormal Laboratory or Physical Exam Result(s) | From the time of informed consent, for approximately 24 months (or earlier if the participant discontinues from the study), and through Safety Follow-up (28 days after the last dose) | |
Secondary | Phase 1: Overall Response Rate (ORR) based on RECIST 1.1 or RANO, as Appropriate to Tumor Type | Phase 1: ORR based on RECIST 1.1 or RANO, as Appropriate to Tumor Type | Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed | |
Secondary | Phase 2: ORR (by Investigator) | Phase 2: ORR (by Investigator) | Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed | |
Secondary | Phase 2: Best Change in Tumor Size from Baseline (by IRC and Investigator) | Phase 2: Best Change in Tumor Size from Baseline (by IRC and Investigator) | Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed | |
Secondary | Phase 2: Duration of Response (DOR; by IRC and Investigator) | Phase 2: DOR (by IRC and Investigator) | Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed | |
Secondary | Phase 2: Central Nervous System (CNS) ORR (by IRC) | Phase 2: CNS ORR (by IRC) | Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed | |
Secondary | Phase 2: CNS DOR (by IRC) | Phase 2: CNS DOR (by IRC) | Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed | |
Secondary | Phase 2: Time to Any and Best Response (by IRC and Investigator) | Phase 2: Time to Any and Best Response (by IRC and Investigator) | every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed | |
Secondary | Phase 2: CBR (by IRC and Investigator) | Phase 2: CBR (by IRC and Investigator) | Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed | |
Secondary | Phase 2: PFS (by IRC and Investigator) | Phase 2: PFS (by IRC and Investigator) | Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed | |
Secondary | Phase 2: Overall Survival (OS) | Phase 2: OS | Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed | |
Secondary | Phase 2: Percentage of Participants with any Serious Adverse Event (SAE[s]) | Phase 2: Percentage of Participants with any SAE(s) | From the time of informed consent, for approximately 24 months (or earlier if the participant discontinues from the study), and through Safety Follow-up (28 days after the last dose) | |
Secondary | Phase 1 and 2: Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve of LOXO-292 (Selpercatinib) | Phase 1 and 2: PK: AUC of LOXO-292 (Selpercatinib) | Cycle 1 Day 1 through Cycle 5 Day 1 (Cycle = 28 days) | |
Secondary | Phase 1 and 2: PK: Maximum Concentration (Cmax) of LOXO-292 (Selpercatinib) | Phase 1 and 2: PK: Cmax of LOXO-292 (Selpercatinib) | Cycle 1 Day 1 through Cycle 5 Day 1 (Cycle = 28 days) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |